Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

Figure 3

Evolution of the DAS28 (disease activity score based on the 28-joint count) scores and its components over time. DAS28 scores at the last clinical evaluation (evaluation at discontinuation of infliximab (IFX) treatment; median 119 weeks, interquartile range = 74 weeks) and the year 4 evaluation (median 205 weeks, interquartile range = 22 weeks). SE, standard error.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us